Strategies & Technologies Driving Drug Discovery to Market
The Lead
Mass Spec Maturing in the Age of Proteomics
June 11, 2013 11:45 am | by Neil Canavan, Contributing Editor | Articles | Comments
Biomarkers are the order of the day—an endogenous signal flare that’s fired, perhaps even before actual disease onset, warning of impending illness. The problem for the clinician, and way before that, the researcher at the bench is how do you detect that tiny, diagnostically incandescent signal.
Globus Faces $16M Payment Over Patent Dispute
June 17, 2013 1:59 pm | News | Comments
Spinal implant manufacturer Globus Medical may have to pay $16 million after a jury decided that...
Teva Buying Microdose for $40M
June 17, 2013 1:25 pm | News | Comments
Teva Pharmaceutical Industries Ltd. is buying MicroDose Therapeutx for $40 million to build its...
Perrigo Acquires Eye-Care Portfolio
June 17, 2013 11:15 am | News | Comments
Perrigo Co. said that it bought the ophthalmic ointment and solution portfolio of Fera...
Clinical Possibilities of Metal–Peptide Complexes
June 17, 2013 5:10 pm | by Archana Gangakhedkar; American Peptide Company Inc., Sunnyvale, Calif. | Articles | CommentsMetal-peptide complexes play an important role in understanding the mechanisms behind complex diseases at the molecular level. Peptides are good chelators for metal ions and can form important tools in the drug and medical device industries.
Valeant Plans $1.75B Stock Offering
June 17, 2013 4:53 pm | News | CommentsValeant Pharmaceuticals will sell $1.75 billion in stock to help fund its $4.5 billion purchase of Bausch + Lomb, to cover fees and expenses related to the deal, and to repay or retire Bausch + Lomb's debt. Valeant agreed to buy Bausch + Lomb in a major expansion of its ophthalmology business.
Simultaneous, Formalin-Free Preservation of Tissue Biomarkers and Morphology for Biomarker Discovery and Biobanking
June 17, 2013 11:47 am | Webinars | CommentsIn this webinar, PreAnalytix will introduce a new technology, the PAXgene Tissue System, which preserves tissue morphology, DNA, RNA, miRNA, proteins, and phosphoproteins in the same sample without cross-linking of biomolecules or damage to the tissue architecture or histomorphology.
Pay-to-Delay Can Be Challenged
June 17, 2013 11:00 am | by Jesse J. Holland | News | CommentsThe Supreme Court ruled that deals between pharmaceutical corporations and their generic drug competitors, which government officials say keep cheaper forms of medicine off the market, can be sometimes be illegal and therefore challenged by federal officials in court.
J&J Acquiring Aragon for $650M
June 17, 2013 10:43 am | News | CommentsJohnson & Johnson said that it has agreed to buy Aragon Pharmaceuticals Inc. for at least $650 million in cash, boosting its position in prostate drug development. The privately-held San Diego, company is focused on the development of drugs to treat hormonally-driven cancers.
Lilly Developing Diabetes Drug
June 17, 2013 9:16 am | News | CommentsEli Lilly and Co. will pay Transition Therapeutics Inc. $7 million and take over the development of a potential diabetes treatment heading into mid-stage clinical testing. Transition could also receive up to $240 million in additional payments, plus royalties if the treatment is eventually approved and sold.
Court to Hear Drug Liability Arguments
June 16, 2013 11:13 am | News | CommentsThe Alabama State Supreme Court is reconsidering a decision allowing makers of name brand drugs to be held liable for injuries caused by generic versions that are made by different companies. The court will hold oral arguments in response to a request that the court reverse an opinion it issued in January.
Mining for Adverse Events
June 15, 2013 12:17 pm | by Christina Smith, News Editor | Articles | CommentsAs electronic medical records continue to debut in hospitals across the country, researchers are exploring ways to optimize the data hidden in clinical notes that could benefit the pharmaceutical community—by finding early signs of potentially harmful drug side effects.
Abbott May Buy Back $3B in Stock
June 14, 2013 1:02 pm | News | CommentsAbbott Laboratories plans to buy back up to $3 billion of its common stock, replacing a finished $5 billion program that began before the health care company separated from its drug business. Abbott makes generic drugs, medical implants, and nutritional formula.
Supreme Court: Genes Can't Be Patented
June 14, 2013 10:56 am | by Linda A. Johnson | News | CommentsThe Supreme Court handed Myriad Genetics Inc. a partial victory in a battle over the validity of patents underlying its test for genes linked to high risk of breast and ovarian cancer. The ruling likely will eventually benefit rivals, as well as doctors and patients wanting to determine the best course of treatment.
Thyroxin Could Target Autism and FAD
June 14, 2013 10:40 am | News | CommentsIn a surprising new finding, a study has found a common molecular vulnerability in autism and fetal alcohol spectrum disorder. Both disorders have symptoms of social impairment and originate during brain development in utero. This damage may be reverseable, however.
Researchers Program Blood Stem Cells
June 14, 2013 10:29 am | News | CommentsBy transferring four genes into mouse fibroblast cells, researchers have produced cells that resemble hematopoietic stem cells, which produce millions of new blood cells in the human body every day. These findings provide a platform for development of cell-replacement therapy.
Lilly Stops Alzheimer's Study
June 13, 2013 5:41 pm | News | CommentsEli Lilly and Co. has stopped a mid-stage clinical trial of an experimental Alzheimer's disease drug because of potential side effects on patients' livers. The company stopped testing LY2886721 because of abnormal results in liver biochemical tests.
CILS Labels Aid Cryogenic Storage
June 13, 2013 11:47 am | Product Releases | CommentsDeveloped for liquid nitrogen freezing and long-term cryogenic freezer storage, laboratory labeling specialists CILS have launched a computer printable durable label for ultra low temperatures, providing immediate permanent adhesion to all cyrovials, tubes, and liquid straws stored down to -196ºC.
Nanotech Improving Tumor Targeting
June 13, 2013 11:31 am | News | CommentsNanotechnology opens up a portal into living tissue that allows scientists to watch cancers spreading, and to determine which parts of a tumor should be targeted. Clinicians can then see where they need to improve on drug delivery to improve clinical outcome.
